Phase II Study Evaluating NALIRIFOX versus Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients with Locally Advanced and Metastatic Pancreatic Adenocarcinoma
- Sponsor:
- MUSC
- Sponsor Study ID:
- 103973
- CTO #:
- 103973
- NCT Number:
- NCT07076212
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Pancreas
- Study Objectives:
- Compare the anti-tumor activity of the NALIRIFOX and mGAP regimens in patients with locally advanced, unresectable, and metastatic PDAC. To assess the safety of the NALIRIFOX and mGAP regimens in patients with locally advanced, unresectable, and metastatic PDAC. To evaluate the anti-tumor activity of the NALIRIFOX and mGAP regimens in patients with locally advanced, unresectable, and metastatic PDAC.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Dincman, Toros, at dincmant@musc.edu .
- Study Coordinator, Concepcion, Holly, at concepch@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina